NovoCure Ltd
No SEC Form 4 filings for $NVCR in the last 30 days.
H.C. Wainwright has reiterated its Buy rating for Novocure (NVCR.US) but has adjusted its target price downwards to $48. This decision reflects the firm's continued positive outlook on the company despite a reduction in the price target.
NovoCure Ltd has announced positive results from its Phase 2 PANOVA-4 trial, which evaluated its innovative Tumor Treating Fields (TTFields) therapy. This non-invasive treatment targets tumor growth, and the company shared further details in an official press release. This news follows recent Japanese government approval for insurance reimbursement of NovoCure's lung cancer treatment and the release of its financial results for Q4 and full year 2025.
Algert Global LLC significantly increased its stake in NovoCure Limited by 372.2% in the third quarter, now owning 0.61% of the company's stock valued at $8.82 million. Other institutional investors also modified their holdings, bringing total institutional ownership to 84.61%. Despite recent insider selling, analysts have a consensus "Hold" rating on NovoCure with a target price of $26.93, following a quarter where the company exceeded EPS estimates but slightly missed revenue projections.
